Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression

Information on the efficacy and safety of molnupiravir in daily clinical practice is very scarce. We aimed to describe the clinical characteristics and outcomes of fully vaccinated patients with mild to moderate breakthrough COVID-19 treated with molnupiravir between January 2022 and February 2022....

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Antonio Vena, Luca Traman, Martina Bavastro, Alessandro Limongelli, Chiara Dentone, Federica Magnè, Daniele Roberto Giacobbe, Malgorzata Mikulska, Lucia Taramasso, Antonio Di Biagio, Matteo Bassetti
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	MDPI AG 2022-07-01
Reeks:	Vaccines
Onderwerpen:	molnupiravir COVID-19 vaccines Intensive care unit admission
Online toegang:	https://www.mdpi.com/2076-393X/10/7/1141
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!